Agbenorku 2011.

Methods	Prospective observational study
Participants	Inclusion criteria: clinically + laboratory‐confirmed BU (exclusion: none stated) Laboratory confirmation: any 2 positives of ZN test for AFB, PCR, and histopathology Enrolled: 189 participants Participant characteristics: 113 males, 60%; age N/A Lesion types: ulcer 145 (76.7%), nodule 38 (20.1%), plaque 6 (3.2%) WHO category I: 44 (22.3%), categories II + III: 145 (76.7%)
Interventions	Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks, with surgery Surgery: all cases Follow‐up: 2 years after discharge from hospital
Outcomes	Healing rate Recurrence Adverse effects Mean hospital stay days Number of new BU cases and their disease stage at the study site after counselling and health education activities Standardized outcome: cure
Notes	Trial location: Ghana Enrolment dates: January 2005 to December 2005
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (Trials)	High risk	—
Allocation concealment (Trials)	High risk	—
Blinding of participants and personnel (Trials)	High risk	—
Blinding of outcome assessment (Trials)	High risk	—
Selection of participants into the study (Prospective observational studies)	Low risk	Selection not related to intervention or outcome.
Measurement of outcomes (Prospective observational studies)	Low risk	Objective outcome measure (healing)
Incomplete outcome data / missing data (All studies)	Low risk	3 participants (3.2%) were lost to follow‐up but for different outcomes.
Selective reporting (All studies)	Low risk	Reported all expected outcomes
Other bias	Low risk	No other bias identified.